Introduction
Lymphomas are a heterogeneous group of malignancies of the lymphoid system that account for B75 000 new tumor cases every year. In lymphoma patients, activation of the fibrinolytic system is frequently reported.
1 However, the mechanism by which the fibrinolytic system modulates tumor/lymphoma growth is not well understood. The fibrinolytic system is known to dissolve fibrin blood clots (fibrinolysis). 2 The serine proteinase plasminogen (Plg) is the main component of the fibrinolytic system and can be converted to the active enzyme, plasmin (Plm), by distinct Plg activators (PA), such as tissue-type Plg activator and urokinase-type Plg activator, which leads to fibrinolysis. The activities of tissue-type Plg activator and urokinase-type Plg activator are regulated by complex formation with PA inhibitors. Aside from fibrinolysis, Plm can activate several matrix metalloproteinases (MMPs) in vitro 3 and in vivo, 4 which are linked to tissue remodeling and various diseases, including lymphoid malignancy. Increased plasma MMP-9 levels were reported in Hodgkin's and non-Hodgkin's lymphoma patients. 5 But the distinct role of MMP-9 and the relation between Plg and MMP-9 in lymphoma growth is still not clear.
The biological and clinical behavior of, for example, T-cell lymphomas, which ranges from aggressive to indolent clinical features, is determined by the balance between tumor growthsupporting and tumor growth-repressive factors in the nonmalignant microenvironment together with contributions from hematopoietic cells. 6 The tumor microenvironment can influence neoplastic progression and growth. 7 MMPs are secreted as inactive proforms and are involved in angiogenesis, cytokine processing, extracellular matrix degradation and invasion during tumor progression. 8, 9 In spite of the importance of MMPs during lymphoma growth, attempts to use MMP inhibitors in cancer therapy have been disappointing in clinical trials due to observed severe side effects. 2 One way to overcome this problem is to control the MMPs by manipulating MMPregulatory factors.
Here, we demonstrate that Plg deficiency, either as a genetic knockout or by pharmacological inducement using YO-2, an active-center-directed inhibitor of Plm, 10 inhibits MMP-9-dependent T-cell lymphoma growth. Using in vivo models, we provide compelling evidence that Plg regulates T-cell lymphoma growth and the influx of myeloid cells into the lymphoma niche in an MMP-9-dependent manner. Thus, Plm is a novel therapeutic target for treatment of certain lymphoid malignancies.
Materials and methods

Mice
WT (Plg þ / þ ) and Plg À/À mice 11 and WT (MMP-9 þ / þ ) and MMP-9 À/À mice (kindly provided by Zena Werb, University of California San Francisco, USA and Leif R Lund, University of Copenhagen, Denmark) were obtained by heterozygous breeding of mice backcrossed into a C57BL/6J background. For the in vivo experiments, all mice were inoculated at age 6-8 weeks. Animal procedures were approved by the Animal Care Committee of Juntendo University. C57BL/6 mice were purchased from SLC, Inc. (Shizuoka, Japan).
Cell lines
B6RV2 cells 12 were cultured in Iscove's modified Dulbecco's medium (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (MP Biomedicals, Aurora, OH, USA), penicillin and streptomycin (WAKO, Osaka, Japan). RMA and FBL3 cells were cultured in RPMI medium 1640 (SIGMA, St Louis, MO, USA) containing 10% fetal bovine serum. EL4T cell lymphoma cells were expanded in RPMI medium 1640 containing 10% fetal bovine serum supplemented with 2 mM L-glutamine, 0.05 mM 2-mercaptoethanol (Invitrogen), penicillin and streptomycin.
In vivo T-cell lymphoma model
The dorsal skin of mice was shaved 1 day before inoculation. The following day, washed lymphoma cells, exceeding 95% cell viability by trypan blue dye exclusion were inoculated into mice (10 8 B6RV2, 5 Â 10 7 FBL3 or 6 Â 10 5 RMA cells per mouse into the dorsal subcutis). Some mice received 10 8 B6RV2 intravenous. Lymphoma length, width and height were measured. Lymphoma volume was calculated as ((length) Â (width) Â (height)). Mice were injected daily with YO-2 or carboplatin or mutant tPA (Eizai, Tokyo, Japan) for the first 5 days at the concentration of 3.8 or 50 or 10 mg/kg body weight, respectively. White blood cells were measured using an automatic blood cell counter MEK-6308 (Nihon Kohden Co., Tokyo, Japan). Survival was monitored.
In vivo CD11b blocking experiment
Mice were inoculated with 10 8 B6RV2 cells subcutaneously and treated with/without 500 mg anti-CD11b (clone 5C6), or with control immunoglobulin G on days 1, 3, 5 and 7. T-cell lymphoma volume was then determined.
Fluorescence-activated cell sorting (FACS)
Harvested T-cell lymphoma tissue was minced. Cell pellets were blocked with an Fc block (clone 2.4G2, BD Pharmingen, San Diego, CA, USA), washed and stained with anti-CD45-Pacific Blue (clone 30-F11, BioLegend, San Diego, CA, USA), antivascular endothelial growth factor (VEGF) receptor-1 (R1)-biotin (clone MF-1, ImClone Systems, New York, NY, USA), anti-F4/ 80-FITC (BM8, BioLegend), anti-Gr-1-FITC (clone RB6-8C5, BD Pharmingen), anti-CD11b-PE (clone M1/70), BD Pharmingen) or anti-CXCR4-FITC (clone 2B11/CXCR4, BD Pharmingen). Cells stained with VEGF-R1-biotin were washed and then incubated with Streptavidin-APC (BD Pharmingen) at 4 1C for 15 min. Dead cells were excluded using propidium iodide staining. Cells were analyzed using a FACSAria machine (BD Biosciences, San Jose, CA, USA).
Immunohistochemistry
Acetone-fixed frozen T-cell lymphoma sections were stained for F4/80. In brief, sections were blocked with the Biotin-Blocking System (Dako, Carpinteria, CA, USA) and 5% goat serum (VECTOR, Burlingame, CA, USA), and incubated overnight at 4 1C with the anti-F4/80 antibody (Ab) (10 mg/ml; clone C1:A3-1, Serotec, Oxford, UK). Rat immunoglobulin G (clone 141 945, R&D Systems Inc., Minneapolis, MN, USA) served as a negative control. Next, endogenous peroxidase was blocked using 3% H 2 O 2 in methanol followed by biotin-labeled rabbit anti-rat immunoglobulin G Ab (clone CLCC40015, Cedarlane Laboratories, Hornby, ON, Canada) and a horseradish peroxidase or Alexa594-conjugated Streptavidin Ab. DAB (WAKO or Alexa 594, Molecular Probes, Eugene, OR, USA), developed sections were counterstained with hematoxylin. Sections were stained with an anti-CD31 Ab (clone: T-2001, BMA, Rockland, ME, USA) followed by a biotin-labeled rabbit anti-rat immunoglobulin G Ab (clone CLCC40015, Cedarlane Laboratories) and an Alexa594-conjugated Streptavidin Ab (Alexa 594, Molecular Probes).
Reverse transcription-PCR
RNA was extracted using Trizol (Invitrogen), followed by a DNase (Nippon Gene, Tokyo, Japan) reaction. The purity and integrity of the extracted RNA was checked spectroscopically and by gel electrophoresis before use. cDNA was generated using a High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA) and was stored at À80 1C. PCR mixtures (12 ml final volume) contained 6 ml of a 2 Â PCR master mix (Promega, Heidelberg, Germany), 1 ml of template cDNA and primers (at a final concentration of 1 mM). Reaction mixtures were incubated in a thermocycler. The respective forward and reverse murine primers used for reverse transcription-PCR were as follows: b-actin: 
Enzyme-linked immunosorbent assay
Mice were bled retro-orbitally using heparin-coated glass capillaries. MMP-9, VEGF-A, and Kit ligand (KitL) plasma levels were measured using the commercially available enzymelinked immunosorbent assay kits (R&D Systems Inc.).
Statistics
Data are reported as the mean±s.e.m. Student t-tests were performed. Po0.05 were considered significant.
Results
Plg and MMP-9 are required for T-cell lymphoma growth
To assess the role of Plg in T-cell lymphoma growth, T-cell lymphoma cells were inoculated subcutaneously into Plg
and WT mice. B6RV2, RMA and FBL3T cell lymphoma growth was delayed in Plg À/À mice compared with WT mice (Figures 1a-c). Daily recombinant tissue-type Plg activator administration accelerated B6RV2 lymphoma growth in WT, but not in Plg À/À mice ( Figure 1a ). We previously demonstrated that Plg can upregulate MMP-9 during tissue regeneration. 4 Plasma MMP-9 levels increased over time in WT, but not in Plg À/À mice compared with WT mice. Overall, these studies provide solid evidence that Plg and MMP-9 have a role in T-cell lymphoma growth.
Plg and MMP-9 are required for myeloid cell infiltration during T-cell lymphoma growth
We next addressed the potential role of Plg and MMP-9 in myeloid cell infiltration. Lymphoma cells were inoculated subcutaneously into Plg À/À , MMP-9 À/À and WT mice and then infiltrating hematopoietic cells were identified by FACS in minced lymphoma tissues using cell markers known to promote angiogenesis or tumorigenesis: Plm inhibitor blocks lymphoma growth by suppressing
The in vivo results above raised the hypothesis that Plg regulates T-cell lymphoma growth via MMP-9. To test this hypothesis, we evaluated the effect of the Plm inhibitor YO-2 against T-cell lymphoma growth. Daily injections of YO-2 reduced T-cell lymphoma growth in WT mice (Figure 3a ), but did not further decrease lymphoma growth in Plg À/À mice ( Figure 3a) . We compared the T-cell lymphoma growth-controlling effect of YO-2 with the antitumor drug carboplatin (Figure 3b ) using the B6RV2T cell lymphoma murine model. Similar tumor growth retardation was observed in the YO-2-treated group compared with the carboplatin-treated group. YO-2 treatment in combination with carboplatin did not further inhibit tumor growth.
Interestingly, YO-2 treatment did not further decrease lymphoma growth in MMP-9 À/À mice (Figure 3c ). Plasma MMP-9 level elevation observed in WT lymphoma-bearing mice was blocked in YO-2-treated lymphoma-bearing WT mice Plg-dependent myeloid cell recruitment into lymphoma M Ishihara et al (Figure 3d ). These results indicate that B6RV2 lymphoma growth is controlled by Plg via MMP-9, and YO-2 can block B6RV2 lymphoma growth. This conclusion suggests that Plg is a direct therapeutic target to tackle lymphoma.
Plg/Plm is the main enzyme among the fibrinolytc system. To test whether other fibrinolytic inhibitors are also applicable to the treatment of T-cell lymphoma, B6RV2-bearing mice were treated with tranexamic acid (TA), a synthetic derivative of the amino-acid lysine, which exerts its anti-fibrinolytic effect through the reversible blockade of lysine binding sites on Plg molecules. TA caused T-cell lymphoma growth retardation, but this effect did not reach significance (Supplementary Figure S2) . TA is a drug that blocks fibrinolysis although it does not inhibit the enzymatic activity of Plm. 16 This indicates that Plg regulate T-cell lymphoma growth independently of its fibrinolytic function.
YO-2 treatment reduced the tissue infiltration of CD45 þ CD11b þ F4/80 þ myeloid cells, and the infiltration of F4/80 þ cells in WT, but not in MMP-9 À/À lymphoma-bearing mice, respectively (Figures 3e and f) . Additionally, the infiltration of CD11b þ Gr-1 þ cells was inhibited in WT mice but not in MMP-9 À/À mice by YO-2 treatment (Supplementary Figure S1) . To identify the hematopoietic cell types within the CD45 þ CD11b þ F4/80 þ cells derived from T-cell lymphoma tissues, we sorted CD45 þ CD11b þ F4/80 þ cells according to their sideward light scatter (SSC) into SSC high and SSC low cells using FACSAria. The SSC high fraction consisted of eosinophils, whereas the SSC low fraction contained mainly monocytes (Figure 4a ). We observed delayed tumor growth in Plg À/À mice injected with B6RV2 or RMA T-cell T-cell lymphoma cells, but not in mice inoculated with the EL4T cell T-cell lymphoma, Lewis lung carcinoma or B16 melanoma cells (data not shown).
We mainly found eosinophils in crushed tumor tissues of B6RV2 and RMA, and monocytes in tumor tissues established using EL4, B16 and Lewis lung carcinoma cells (Figure 4b ). AntiCD11b treatment reduced T-cell lymphoma growth in WT mice and no significant further T-cell lymphoma growth retardation was observed in anti-CD11b-treated Plg À/À mice (Figure 4c ). In mice challenged intravenously with lymphoma cells, treatment with Plm inhibitor YO-2 prolonged the survival compared with the phosphate-buffered saline-treated group (Figure 4d) , although the white blood cell counts were not significantly different between both groups (Figure 4e) . Indeed, treatment of YO-2 in vitro did not affect lymphoma cell proliferation (data not shown). These data indicate that YO-2 improved the survival of lymphoma-inoculated mice not by suppressing the proliferation of B6RV2 cells but by modulating the local lymphoma microenvironment. Taken together, these results suggest that YO-2, a specific Plm inhibitor, can reduce T-cell lymphoma growth through regulating MMP-9-dependent CD11b þ /F4/80 þ myeloid cell recruitment.
Plm inhibitor blocks cytokine increase during T-cell lymphoma growth
Protease-cytokine interactions are important in the remodeling of the T-cell lymphoma microenvironment in T-cell lymphoma growth. Recent reports have indicated that tumor-infiltrating myeloid cells are a source for local cytokine release into the tumor microenvironment in vivo and related to tumor malignancy. 17, 18 We examined T-cell lymphoma growth-associated cytokine expression in FACS-isolated CD45 Plg-dependent myeloid cell recruitment into lymphoma M Ishihara et al transforming growth factor-b 1, VEGF-A and c-Kit. The former factors are known to influence the survival and proliferation of T-cell lymphoma cells. 17 Plg or MMPs can liberate VEGF-A from extracellular matrix stores. 19 Augmented plasma VEGF-A levels were observed in T-cell lymphoma-bearing WT, but not in Plg À/À mice (Figure 5b ), in YO-2-treated WT mice, nor in MMP-9 À/À mice with or without YO-2 treatment (Figure 5c ). VEGF-A is a well-known angiogenic factor. But surprisingly, Plg deficiency did not result in reduced vessel density in B6RV2T cell lymphoma tissues when compared with WT controls (Supplementary Figure S3 ), implying that the reduced T-cell lymphoma growth was not due to impaired angiogenesis. It has been shown that VEGF-A induces hematopoietic cell mobilization and myeloid cell differentiation. 20, 21 KitL also induces myeloid cell differentiation. 22 Plasma KitL levels were increased in T-cell lymphomabearing WT, but not in Plg À/À mice (Figure 5d ), but did not 
þ cells were gated into SSC high and SSC low cells and were isolated by FACSAria. The SSC high fraction consisted of eosinophils, whereas the SSC low fraction mainly contained monocytes as visualized on May Grunwald-stained slides. (b) Relative contribution of different hematopoietic cell types within the tumor-infiltrating CD45 þ CD11b þ cell population isolated from various murine tumors. (n ¼ 3). (c) B6RV2-injected Plg À/À and WT mice were treated with anti-CD11b or control antibodies (n ¼ 3; *Po0.05; **Po0.01). Tumor volume was measured. (d) WT mice were injected intravenously with B6RV2 followed by treatment with phosphate-buffered saline or YO-2 and survival rate was observed. Statistic analysis using log rank test showed P-value of 0.0395 (n ¼ 7). (e) WT mice were injected intravenously with B6RV2 followed by treatment with PBS (phosphatebuffered saline) or YO-2. White blood cell (WBC) count was measured (n ¼ 4). Plg-dependent myeloid cell recruitment into lymphoma M Ishihara et al rise in T-cell lymphoma-bearing mice with drug-or geneticallyinduced Plg deficiency, with MMP-9 deficiency with or without YO-2 treatment (Figure 5e ). Interestingly, the peak of infiltration of CD11b þ F4/80 þ cells into T-cell lymphoma tissues coincided with peak plasma KitL levels in T-cell lymphoma-bearing WT mice (data not shown). Lymphoma patients show abnormal plasma levels of cytokines produced primarily by lymphoma cells or secondarily by stromal cells. 23 Myeloid cells can provide proangiogenic factors such as VEGF-A and MMP-9. 24 VEGF-A can be liberated from extracellular matrix stores after Plg or MMP activation. 19 Our data demonstrate that Plg activation during lymphoma growth controls plasma VEGF-A levels via MMP-9 modulation. Indeed, we showed that VEGFR1 was required for myeloid cell recruitment into B6RV2 lymphoma tissues in vivo. 25 We have shown that activation of MMP-9 by Plm can expand the myeloid cell pool and mobilize proangiogenic myeloid cells, a process dependent on VEGF-A and KitL. 4 Here, our findings indicate that Plm activation during Tcell lymphoma growth increases plasma VEGF-A and KitL levels and recruits CD11b þ F4/80 þ cells into T-cell lymphoma tissues.
Discussion
The tumor microenvironment including immune cells, fibrosis and angiogenesis can influence the survival of lymphoma patients after treatment. 26 Our study provides in vivo evidence that Plg regulates T-cell lymphoma growth upstream of MMP-9, and controls both the infiltration of CD45 þ CD11b þ F4/80 þ into T-cell lymphomas and the release of stromal cell-associated growth factors. We propose that targeted inhibition of Plg is a new therapeutic approach that can control T-cell lymphoma growth by modulating the T-cell lymphoma microenvironment. We showed that T-cell lymphoma growth in a T-cell lymphoma model was retarded in MMP-9 À/À mice and that Plm inhibitors failed to further decrease the already low T-cell lymphoma growth in MMP-9-deficient mice. Other protumorgenic targets of Plg aside from MMP-9 are conceivable, for example, MMP-3, as Plm also activate pro-MMP-1, pro-MMP-3 and pro-MMP13 (refs 27,28) or pro-tumorgenic growth factors and cytokines such as basic fibroblast growth factor. 29 A study using a spontaneous T-cell lymphoma model demonstrated that MMP-9 deficiency in lymphoma cells resulted in a drop in survival time caused by increased tumor metastasis. 30 Further studies will be necessary to unravel the role of Plg and MMP in the invasion and metastasis of T-cell lymphoma cells.
As previously stated, Plm induces fibrinolysis. 2 Recently, tumor growth dependence on fibrinogen has been linked to the anatomic location of the tumor. 31 Tumor growth of Lewis lung carcinoma was sustained in Plg À/À mice when transplanted into the dorsal skin but was suppressed in the footpad, where vasoocclusive thrombi occurrence limited tumor blood supply. Fibrinogen deficiency restored tumor growth in footpadtransplanted Plg À/À mice. How is T-cell lymphoma growth controlled by Plm/the fibrinolytic system? Plm deficiency, either genetically-induced (Plg À/À mice) or drug-induced (treatment with YO-2, an inhibitor of Plm), blocked T-cell lymphoma growth, indicating that Plg activation was required for T-cell lymphoma growth. YO-2 treatment inhibited T-cell lymphoma growth as efficiently as genetic deletion of Plg. Although YO-2 blocked the T-cell lymphoma growth, TA administration to the T-cell lymphoma model did not cause T-cell lymphoma growth delay (Supplementary Figure S2) . TA is a drug that blocks fibrinolysis, but can accelerate Plm formation in vitro. 16 We therefore proposed that T-cell lymphoma growth retardation was due to the action of Plm, rather than to that of fibrinogen. Further studies will be necessary to prove this hypothesis.
Infiltrating innate immune cells support lymphoma cell survival and/or proliferation and correlate with a poor prognosis. 32 We show that CD45 þ CD11b þ F4/80 þ myeloid cell influx requires the presence of both MMP-9 and Plm whereas infiltration of CD11b þ Gr-1 þ myeloid cells into T-cell lymphoma tissues is Plg dependent, but is independent of MMP-9. The importance of CD11b þ cells for T-cell lymphoma growth was confirmed in the studies using neutralizing antibodies against CD11b. T-cell lymphoma growth was inhibited in WT mice and could not be further blocked in Plg À/À mice, indicating that the role of Plg for T-cell lymphoma growth was driven by its ability to regulate CD11b þ cell migration. A role of Plg in CD45 þ cell migration into the medial layer of allografted vascular tissue in graft vascular disease model has been reported. 33 Cytokines and chemokines released from tumor cells can regulate the influx of hematopoietic cells. Plg-dependent tumor inhibition was observed in tumors in which a high rate of infiltrating eosinophils had been detected. We observed increased KitL levels in lymphoma-bearing mice, which was blocked in Plg-deficient mice. KitL can recruit c-kit receptorpositive eosinophils. 34 Eotaxin, a potent eosinophil chemotactic factor promotes eosinophil transmigration via the activation of the Plg-Plm system 35 Further studies will be necessary to understand whether these or other factors released from tumor cells have a role for the observed impaired influx of myeloid cells into tumors after Plm inhibition. The role of eosinophils is controversial in different types of malignancies as both growth promoting and inhibitory effects had been described. 36 Further studies will be needed to understand the role of eosinophils in T-cell lymphoma and to establish a role for Plg in the regulation of other eosinophilia-associated diseases. In our model, CD45
þ CD11b þ F4/80 þ cells expressed cytokines such as VEGF-A and transforming growth factor-b. These factors are known to accelerate lymphoma growth. 37 These studies support our findings that myeloid cell infiltration is dependent on the activation of the Plg/MMP-9 pathway. Furthermore, multiple reports have shown that myeloid cells mediate key steps of tumor progression. 38 In conclusion, we show that the Plg/MMP-9 pathway can regulate T-cell lymphoma growth and accelerate the recruitment of T-cell lymphoma growth supportive CD45 þ CD11b þ F4/80 þ myeloid cells into T-cell lymphoma tissues. Therefore, targeting the Plg/MMP-9 pathway (for example, using YO-2) should offer a new approach for therapeutic intervention in lymphoid malignancy.
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